Asparlas (Calaspargase PEGol-Mknl) Patent Expiration, LOE Window & CMS Spending

Asparlas (Calaspargase PEGol-Mknl) by Servier: Biologic BLA (Purple Book Regime), 0 AB generics, $13.5M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorServier
FDA Application & PathwayB761102 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$13.5M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$13.5M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 18.2% 2-yr change)